PARSIPPANY, N.J., Aug. 4 /PRNewswire/ — Daiichi Sankyo, Inc.
and its parent company, Daiichi Sankyo Co., Ltd, (collectively,
“Daiichi Sankyo”) have reached an agreement with Apotex Inc. and
Apotex Corp. (collectively, “Apotex”) to settle their patent
litigation involving Apotex’s challenge to Daiichi Sankyo’s U.S.
Patent Number 5,340,821 (hereinafter referred to as “the ‘821
patent”) covering Evoxac® (cevimeline HCl). Under the
agreement, Apotex has received a license to the ‘821 patent that
will permit Apotex to commercially launch its generic cevimeline
HCl product in the fourth quarter of 2012.
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply
of innovative pharmaceutical products to address the diversified,
unmet medical needs of patients in both mature and emerging
markets. While maintaining its portfolio of marketed
pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments
for thrombotic disorders and focused on the discovery of novel
oncology and cardiovascular-metabolic therapies. Furthermore, the
Daiichi Sankyo Group has created a “Hybrid Business Model,” which
will respond to market and customer diversity and optimize growth
opportunities across the value chain. For more information, please
visit www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of
the Daiichi Sankyo Group. For more information on Daiichi Sankyo,
Inc., please v
‘/>”/>
